• Like

Smoking cessation drugs world market prospects 2013 2023

  • 350 views
Uploaded on

For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: …

For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1118/Smoking-Cessation-Drugs-World-Market-Prospects-2013-2023

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
350
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
8
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision- gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur- chase and single copy is for personal use only. Smoking Cessation Drugs: World Market Prospects 2013-2023
  • 2. www.visiongain.com Contents 1.1 Smoking Cessation Drugs: World Market Overview 1.2 Aims and Format of the Report 1.3 Research and Analysis Methods 1.4 Scope of the Report 2.1 Tobacco- What is All the Fuss About? 2.1.1 How is Tobacco Consumed? 2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide 2.2 Smoking Causes Many Health Disorders 2.3 Nicotine Addiction is at the Root of Smoking 2.4 Smoking Cessation 2.4.1 Why is it Difficult to Stop Smoking? 2.4.2 How Can Smokers Quit? 3.1 How Will the Smoking Cessation Market Develop Until 2023? 3.2 Smoking Cessation Drugs Market by Type of Sale 3.2.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2012 3.2.1.1 OTC Smoking Cessation Drugs: Forecast, 2013-2023 3.2.2 Prescription (Rx) Smoking Cessation Drugs, 2012 3.2.2.1 Prescription Smoking Cessation Drugs: Forecast, 2013-2023 3.3 Smoking Cessation Drugs by Mechanism of Action 3.3.1 Nicotine Replacement Therapy 3.3.1.1 Nicotine Replacement Therapy, 2012 3.3.1.2 Nicotine Replacement Therapy Forecast, 2013-2023 1. Executive Summary 2. Introduction to Smoking Cessation 3. World Smoking Cessation Drugs Market, 2013-2023
  • 3. www.visiongain.com Contents 3.3.2 Nicotine Receptor Partial Agonist Drugs 3.3.2.1 Nicotine Receptor Partial Agonist Drugs, 2012 3.3.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023 3.3.3 Antidepressants 3.3.3.1 Antidepressants for Smoking Cessation, 2012 3.3.3.2 Antidepressants for Smoking Cessation: Forecast, 2013-2023 4.1 Major Geographical Markets for the Smoking Cessation Industry in 2012 4.2 The US is Still the Market Leader 4.2.1 Smoking Prevalence Declining in the US 4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US 4.2.3 US Smoking Cessation Market Revenue, 2012 4.2.4 US Smoking Cessation Market Forecast, 2013-2023 4.2.5 Scope for US Smoking Cessation Market Expansion 4.3 The Japanese Smoking Cessation Market has Potential to Expand in Revenues 4.3.1 Japan has a Less Developed Smoking Cessation Market 4.3.2 The Japanese Smoking Cessation Market, 2012 4.3.3 Japanese Smoking Cessation Market Forecast, 2013-2023 4.4 The EU-5 Smoking Cessation Drugs Market 4.4.1 The UK Smoking Cessation Market 4.4.1.1 Tobacco Use in the UK 4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT 4.4.1.3 The UK has Strong Anti-Smoking Legislation 4.4.1.4 UK Smoking Cessation Market, 2012 4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023 4. Leading National Markets for Smoking Cessation Drugs to 2023
  • 4. www.visiongain.com Contents 4.4.2 The French Smoking Cessation Market 4.4.2.1 Tobacco Use in France is Still High 4.4.2.2 The French Smoking Cessation Market, 2012 4.4.2.3 French Smoking Cessation Market Forecast, 2013-2023 4.4.2.4 Factors Influencing the Development of the French Market 4.4.3 The Spanish Smoking Cessation Market 4.4.3.1 Tobacco Use in Spain is Low 4.4.3.2 The Spanish Smoking Cessation Market, 2012 4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2013-2023 4.4.3.4 Spain’s Anti-smoking Laws are Very Robust 4.4.4 The Italian Smoking Cessation Market 4.4.4.1 Reducing Tobacco Use in Italy is a Government Priority 4.4.4.2 The Italian Smoking Cessation Market, 2012 4.4.4.3 The Italian Smoking Cessation Market Forecast, 2013-2023 4.4.4.4 Italy has a Decades-Long Commitment to Reducing Smoking 4.4.5 The German Smoking Cessation Market 4.4.5.1 Germany is a Smoker’s Citadel 4.4.5.2 The German Smoking Cessation Market, 2012 4.4.5.3 German Smoking Cessation Market Forecast, 2013-2023 4.4.5.4 Germany Has a Relaxed Attitude to Smoking 4.5 The BRIC Smoking Cessation Drugs Market is Untapped 4.5.1 The Brazilian Smoking Cessation Market 4.5.1.1 Tobacco Use in Brazil is Pervasive 4.5.1.2 The Brazilian Smoking Cessation Market, 2012 4.5.1.3 Brazilian Smoking Cessation Market Forecast, 2013-2023 4.5.1.4 Smoking Cessation Market Prospects in Brazil Look Bright 4.5.2 The Russian Smoking Cessation Market 4.5.2.1 Tobacco Use in Russia Forms a Serious Problem
  • 5. www.visiongain.com Contents 4.5.2.2 The Russian Smoking Cessation Market, 2012 4.5.2.3 Russian Smoking Cessation Market Forecast, 2013-2023 4.5.2.4 The Russian Government has started to Take Positive Steps 4.5.3 The Indian Smoking Cessation Market: Vast Possibilities 4.5.3.1 India’s Attitudes to Tobacco 4.5.3.2 The Indian Smoking Cessation Market, 2012 4.5.3.3 Indian Smoking Cessation Market Forecast, 2013-2023 4.5.3.4 Indian Smoking Cessation Market Still in its Infancy 4.5.3.5 Prospects for Growth of the Indian Smoking Cessation Market 4.5.4 The Chinese Smoking Cessation Market 4.5.4.1 Tobacco use in China is Unprecedented 4.5.4.2 The Chinese Smoking Cessation Market, 2012 4.5.4.3 Chinese Smoking Cessation Market Forecast, 2013-2023 4.5.4.4 The Chinese Smoking Cessation Market is Under Developed 4.5.4.5 China’s Economic Progress Could be Hindered by Tobacco Use 5.1 The Top 5 Brands Claimed Most of the Market in 2012 5.2 Nicotine Replacement Therapy is a Main Component of the Market 5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK) 5.2.2 Nicorette (Johnson & Johnson/GSK) 5.2.3 Nicotinell (Novartis) 5.2.4 Other NRT Products 5.3 Champix/Chantix (Varenicline, Pfizer) 5.3.1 Champix/Chantix Sales Performance, 2012-2023 5.3.2 Champix/Chantix May Help in Treating Other Addictions 5.4 Zyban (Bupropion, GSK) 5. Leading Smoking Cessation Products: Outlook to 2023
  • 6. www.visiongain.com Contents 5.4.1 Zyban Sales Forecast, 2012-2023 5.5 Tabex – One to Watch Out For 5.6 Other Smoking Cessation Aids 5.6.1 Smokeless Tobacco 5.6.1.1 E-Cigarettes 5.6.1.2 Snus/Snuff 5.6.1.3 Gutkhas 5.6.2 CigRx Dietary Supplement 5.6.3 Dissolvable Tobacco 5.6.4 Behavioural Therapy 6.1 Nicotine Vaccines: Hype or Hope? 6.1.1 TA-Nic (Celtic Pharma) 6.1.2 Niccine (Independent Pharmaceutica AB) 6.1.3 SEL-068 (Selecta Biosciences) 6.2 Monoamine Oxidase Inhibitors 6.3 Cannabinoid Receptor-1 Antagonists 6.4 Dopamine D3 Antagonists 6.5 Opiate Antagonists 6.6 ARD-1600 (Aradigm) 6.7 EMB-001(Embera NeuroTherapeutics) 6.8 Meclizine (Duke University/Philip Morris Products) 6.9 Other Smoking Cessation Aids Under Development 6.9.1 X22 TM (22 nd Century Group) 6.9.2 Other Developments 6. Smoking Cessation R&D Pipeline Analysis
  • 7. www.visiongain.com Contents 7.1 The Smoking Cessation Market was Dominated by Four Companies, But for How Long? 7.2 SWOT and STEP Analysis of the Smoking Cessation Market 7.2.1 Strengths of the Smoking Cessation Industry 7.2.1.1 Innovation in Smoking Cessation Therapies 7.2.1.2 Innovative Marketing 7.2.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy 7.2.1.4 OTC Switching 7.2.1.5 Widespread Coverage of Smoking Cessation Products 7.2.2 Weaknesses of the Smoking Cessation Industry 7.2.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking 7.2.2.2 Currently-Marketed Smoking Cessation Therapies – Relapse Rate 7.2.2.3 Concerns Regarding the Development of Addiction to NRTs 7.2.3 Opportunities for the Smoking Cessation Industry 7.2.3.1 Smoking is Prevalent Worldwide and Slowly Increasing 7.2.3.2 Countries with Untapped Smoking Cessation Market Potential 7.2.3.3 Growth of Emerging-Economy Smoking Cessation Markets 7.2.3.4 Health Effects of Tobacco 7.2.3.5 Economic and Social Impact of Tobacco on Society 7.2.3.6 Framework Convention on Tobacco Control (FCTC) 7.2.3.7 Government-Sponsored Smoking Cessation Programmes 7.2.3.8 Increasing Tobacco Taxes 7.2.3.9 Smoking Bans 7.2.3.10 Warning Information on Tobacco Products 7.2.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship 7.2.3.12 Upcoming Launch of Tabex 7.2.4 Threats to the Smoking Cessation Industry 7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023
  • 8. www.visiongain.com Contents 7.2.4.1 Concern over Side-Effects of Smoking Cessation Drugs 7.2.4.2 Lack of Reimbursement for Smoking Cessation Therapies 7.2.4.3 Traditional Smokeless Tobacco 7.2.4.4 The E-Cigarette 8.1 Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma 8.1.1 On Sopharma’s Geographical Focus 8.1.2 On the Availability of Tabex 8.1.3 On the Efficacy of Tabex in Comparison to Other Products 8.1.4 On Any Other Points of Interest 8.2 Interview with Mr Rick Stewart, CEO, Extab Corporation 8.2.1 On Tabex’s Release 8.2.2 On Tabex vs. Other Smoking Cessation Treatments 8.2.3 On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations 8.2.4 On the Future Direction of the Industry 8.2.5 On Any Other Points of Interest 8.3 Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems 8.3.1 Unmet Needs 8.3.2 Major Areas of Focus 8.3.3 Smoking Cessation R&D Pipeline 8.3.4 Opportunities for Revenue Growth 8.3.5 Market Drivers 8.4 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of London 8.4.1 Unmet Needs 8. Research Interviews
  • 9. www.visiongain.com Contents 8.4.2 Major Areas of Focus and R&D Pipeline 8.4.3 Opportunities for Revenue Growth 8.4.4 Market Drivers 9.1 Smoking is the Main Cause of Preventable Deaths Worldwide 9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013 to 2023 9.3 World Smoking Cessation Market: Prospects to 2023 9.4 Market Drivers 9.5 Leading and Emerging Smoking Cessation Markets 9.6 Concluding Remarks 9. Conclusions of the Study
  • 10. www.visiongain.com Contents Table 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.2 World Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 3.3 Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023 Table 3.4 Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.5 OTC Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 3.6 Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023 Table 3.7 Prescription Smoking Cessation Drivers and Restraints, 2012-2023 Table 3.8 Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023 Table 3.9 Nicotine Replacement Therapy Market Forecast ($m), 2012-2023 Table 3.10 Nicotine Replacement Therapy Drivers and Restraints, 2012-2023 Table 3.11 NRPA Market Forecast ($m), 2012-2023 Table 3.12 NRPA Drivers and Restraints, 2012-2023 Table 3.13 Antidepressants Market Forecast ($m), 2012-2023 Table 3.14 Antidepressants Market Drivers and Restraints, 2012-2023 Table 4.1 Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023 Table 4.2 Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading Countries, 2012 Table 4.3 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Table 4.4 US Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Table 4.6 Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023 Table 4.7 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.8 EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023 Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.10 French Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.11 Spanish Smoking Cessation Market Forecast ($m), 2012-2023 List of Tables
  • 11. www.visiongain.com Contents Table 4.12 Italian Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.13 German Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.14 BRIC Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.15 BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023 Table 4.16 Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.17 Russian Smoking Cessation Market Forecasts ($m), 2012-2023 Table 4.18 Indian Smoking Cessation Market Forecast ($m), 2012-2023 Table 4.19 Chinese Smoking Cessation Market Forecast ($m), 2012-2023 Table 5.1 Top 5 Smoking Cessation Drugs’ Sales ($m) and Market Shares (%), 2012 Table 5.2 Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023 Table 5.3 Nicotine Replacement Therapy Types, 2012 Table 5.4 NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012 Table 5.5 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023 Table 5.6 NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023 Table 5.7 Nicorette NRT Brands, 2012 Table 5.8 Nicorette Sales Forecast ($m), 2012-2023 Table 5.9 Nicorette Drivers and Restraints, 2012-2023 Table 5.10 Nicotinell Sales Forecast ($m), 2012-2023 Table 5.11 Nicotinell Drivers and Restraints, 2012-2023 Table 5.12 Champix/Chantix Sales Forecast ($m), 2012-2023 Table 5.13 Champix/Chantix Drivers and Restraints, 2012-2023 Table 5.14 Zyban Sales Forecast ($m), 2012-2023 Table 5.15 Zyban Drivers and Restraints 2012-2023 Table 5.16 Tabex Sales Forecast ($m), 2012-2023 Table 5.17 Tabex Drivers and Restraints, 2012-2023 Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013 Table 6.2 Smoking Cessation R&D Pipeline: Apparent Disappointments
  • 12. www.visiongain.com Contents Table 7.1 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2012 Table 7.2 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2023 Table 7.3 Other Companies Operating in the Smoking Cessation Industry Table 7.4 SWOT Analysis of the Industry and Market, 2012-2023 Table 7.5 STEP Analysis of the Industry and Market, 2012-2023 Table 9.1 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx, 2013, 2017 & 2023 Table 9.2 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type, 2013, 2017 & 2023 Table 9.3 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading Countries, 2013, 2017 & 2023
  • 13. www.visiongain.com Contents Figure 2.1 Smoking-Related Health Disorders Figure 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023 Figure 3.2 Smoking Cessation Market Shares (%) by Type of Sale, 2012 Figure 3.3 OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 3.4 Rx Smoking Cessation Market Forecast ($m), 2012-2023 Figure 3.5 Smoking Cessation Market Shares (%) by Drug Type, 2012 Figure 3.6 NRT Market Forecast ($m), 2012-2023 Figure 3.7 NRPA Market Forecast ($m), 2012-2023 Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023 Figure 4.1 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012 Figure 4.2 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2017 Figure 4.3 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2023 Figure 4.4 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023 Figure 4.6 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023 Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.8 French Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.9 Spanish Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.10 Italian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.11 German Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.12 BRIC Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.13 Brazilian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.14 Russian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.15 Indian Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.16 Chinese Smoking Cessation Market Forecast ($m), 2012-2023 List of Figures
  • 14. www.visiongain.com Contents Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2012 Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023 Figure 5.3 Nicorette Sales Forecast ($m), 2012-2023 Figure 5.4 Nicotinell Sales Forecast ($m), 2012-2023 Figure 5.5 Champix/Chantix Sales Forecast ($m), 2012-2023 Figure 5.6 Zyban Sales Forecast ($m), 2012-2023 Figure 5.7 Tabex Sales Forecast ($m), 2012-2023 Figure 7.1 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012 Figure 7.2 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023 Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023 Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 & 2023
  • 15. www.visiongain.com Contents 22 nd Century Group Action on Smoking on Health (ASH) Advent Life Sciences Alkermes American Heart Association (AHA) American Lung Association (ALA) Aradigm Australian Therapeutic Goods Administration BGP Group Boots Cochrane Collaboration Cambrex Campaign for Tobacco-Free Kids Cancer Centre and Institute of Oncology Ceejay Healthcare Celtic Pharma Centers for Disease Control and Prevention (CDC) Cephalon China National Tobacco Corporation CN Creative Cytos Biotechnology Duke University Embera NeuroTherapeutics European Medicines Agency (EMA) Evolution Health Systems Evotec Organisations Mentioned
  • 16. www.visiongain.com Contents Excelsa Pharma Extab Corporation Fertin Pharma A/S Food and Drug Administration (US FDA) GlaxoSmithKline (GSK) Haihang Industry Company Health Canada Independent Pharmaceutica AB Japanese Ministry of Health, Labour and Welfare (MHLW) Japan Tobacco Johnson & Johnson Karolinska Institutet LEO Pharma LSU Health Sciences Center – Shreveport Mayo Clinic Medicines and Healthcare Products Regulatory Agency (MHRA) Nabi Biopharmaceuticals National Cancer Institute (NCI) National Health Service (UK NHS) National Institute for Health and Clinical Excellence (UK NICE) National Institute on Drug Abuse (NIDA) Next Safety Nicobrand Niconovum AB Nicoventures Novartis Nulife Nu-Mark
  • 17. www.visiongain.com Contents Perrigo Pfizer Philip Morris Products S.A Queen Mary University of London Revolymer R.J. Reynolds Tobacco Company Rock Creek Pharmaceuticals Roche Ruyan Sanofi Selecta Biosciences Sopharma Spanish Ministry of Health, Social Services and Equality Star Scientific Taj Pharmaceuticals Target Corporation Teva Pharmaceutical Industries Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry Tobacco Manufacturers Association University College London (UCL) UK Centre for Tobacco Control Studies Walmart Wolfson Institute of Preventive Medicine World Bank World Health Organization (WHO) Zenara
  • 18. Page 54www.visiongain.com Smoking Cessation Drugs: World Market Prospects 2013-2023 • Sublingual tablets. Other NRT products are sold only at pharmacies and include the following: • Inhalers • Nasal spray. In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) considered proposals to end restricting sales of inhalers and nasal spray to pharmacies. This has led to availability of these NRT products in other retail outlets, in addition to pharmacies. 4.4.1.3 The UK has Strong Anti-Smoking Legislation A ban on smoking in public places in the UK lifted the UK smoking cessation market by 2009. Currently, the UK is the largest European smoking cessation market and the second-largest in the world. The UK Government has been active in discouraging smoking in recent years. Smoking cessation products have been reimbursed by the NHS since 2001. In addition, since October 2007 it has become illegal in the UK to sell tobacco to people under the age of 18 (previously it was 16). All forms of tobacco advertising have also been banned, and there is a virtual blanket ban on smoking in all enclosed public spaces, such as offices and restaurants. All of these measures are helping to reduce the prevalence of smoking in the UK, and visiongain expects this to, in turn, provide a boost to the smoking cessation drug market in the UK over the forecast period. 4.4.1.4 UK Smoking Cessation Market, 2012 In 2012, the UK smoking cessation market was worth $177m, and this represents an increase of 1.31% over the previous year’s revenue figure of $174m 4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023 The UK smoking-cessation market is the largest in Europe and the government has been vigorous in introducing bans on smoking and promoting smoking cessation plans and products. Visiongain therefore believes that the market for smoking cessation drugs market will grow moderately from 2013 to 2023. The UK Government's strong anti-smoking agenda, including its willingness to reimburse smoking cessation products, will provide a strong impetus for smokers to stop smoking. This will lead to increased sales of smoking cessation products, visiongain concludes.
  • 19. Page 55www.visiongain.com Smoking Cessation Drugs: World Market Prospects 2013-2023 The general public in the UK is aware of the dangerous effects of smoking and the availability of smoking cessation products. Visiongain predicts that the UK smoking cessation market will therefore show increasing growth rate at a modest pace. Starting at a value of $179m in 2013, by 2017, the size of the UK market will have increased to $209m at a CAGR of 3.89%. Moreover, by 2023, the market size would have increased to $289m, at a CAGR of 4.89%. 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 UK ($m) 174 177 179 184 190 199 209 221 235 249 264 277 289 Annual Growth (%) 1.31 1.68 2.57 3.40 4.31 5.29 5.91 6.07 6.16 5.75 5.04 4.47 CAGR (%, from 2013) 3.89 4.89 4.4.2 The French Smoking Cessation Market 4.4.2.1 Tobacco Use in France is Still High There are an estimated 15 million tobacco smokers in France, representing a national prevalence of 29% among people aged 15 years or older (35% among men and 23% among women). Smoking prevalence has remained fairly stable in the last five years and does not appear to have been greatly affected by the ban on smoking in pubic places, which began on 1st January 2007. 0 50 100 150 200 250 300 350 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 UKRevenues($m) Year Source: visiongain 2013 Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023 Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023 Source: visiongain 2013